Invenio previously announced that the FDA granted Breakthrough Device Designation for NIO Lung Cancer Reveal, an investigational AI image-analysis module designed to assist physicians in evaluating images from fresh bronchoscopic lung forceps biopsy specimens acquired with the NIO Laser Imaging System. The investigational module is not cleared or approved for clinical use in the United States. With its expanded Board, Invenio remains focused on commercialization and broadening access to its platform to supp ...